Related Experiment Videos
[Serum stefin A in patients with type 2 diabetes]
Agnieszka Piwowar1, Izabela Fus, Maria Kanapik-Kordecka
1Katedra i Zakład Biochemii Farmaceutycznej we Wrocławiu. piwowar@bf.uni.wroc.pl
Polskie Archiwum Medycyny Wewnetrznej
|July 3, 2004
Summary
Plasma stefin A levels are elevated in type 2 diabetes patients, particularly those with obesity and vascular complications. This suggests stefin A
Area of Science:
- Biochemistry
- Endocrinology
- Immunology
Context:
- Stefin A is an intracellular inhibitor of human lysosomal cysteine proteinases.
- Plasma stefin A concentration reflects systemic expression and organism-wide immunity.
- Type 2 diabetes is associated with increased risk of vascular complications.
Purpose:
- To investigate plasma stefin A concentrations in type 2 diabetes patients.
- To determine if stefin A levels correlate with vascular complications, BMI, or glycemic control.
- To explore the relationship between stefin A, cathepsin B (CB), and N-acetyl-beta-D-glucosaminidase (NAG) activities.
Summary:
- Plasma stefin A levels were significantly higher in type 2 diabetes patients (4.95 µg/l) compared to controls (2.80 µg/l).
- Elevated stefin A was most pronounced in patients with macrovascular complications (7.70 µg/l) and in those who were overweight or obese.
- No significant association was found between stefin A levels and glycemic control, but a positive correlation with increasing NAG activity was observed.
Impact:
- Stefin A may play a role in the pathogenesis of vascular complications in type 2 diabetes.
- Findings suggest a link between stefin A, obesity, and diabetes-related vascular issues.
- This research highlights stefin A as a potential biomarker for complications in type 2 diabetes.